Estimating Medicare and patient savings from the use of bevacizumab for the treatment of exudative age-related macular degeneration

The Medicare cost savings from the use of bevacizumab in the United States for the treatment of exudative age-related macular degeneration (AMD) were estimated by replacing the use of bevacizumab with ranibizumab and aflibercept.

Source: American Journal of Ophthalmology - April 12, 2018 Category: Opthalmology Authors: Philip J. Rosenfeld, Matthew A. Windsor, William J. Feuer, Sissi J.J. Sun, Kevin D. Frick, Eric A. Swanson, David Huang Tags: Original Articles Source Type: research